U
SCLN

UBS’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

UBS’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$83K Sell
12,147
-2,367
-16% -$14.2K ﹤0.01% 6223
2014
Q2 		$77K Sell
14,514
-569
-4% -$2.77K ﹤0.01% 6284
2014
Q1 		$68K Sell
15,083
-2,384
-14% -$11.5K ﹤0.01% 6457
2013
Q4 		$88K Buy
17,467
+11,467
+191% +$55.2K ﹤0.01% 6226
2013
Q3 		$30K Sell
6,000
-17,028
-74% -$94.8K ﹤0.01% 7561
2013
Q2 		$114K Buy
+23,028
New +$110K ﹤0.01% 5743

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QBFM
QS Batterymarch Financial Management New York $3.78B AUM 22.02% 1-Year Est. Return

UBS's SCLN Position: Q3 2014 in Review

UBS reduced its Sciclone Pharmaceuticals Inc (SCLN) stake by 16% in Q3 2014, selling an estimated $14.2K and leaving 12,147 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #6223.

UBS first reported a position in SCLN in Q2 2013 and has held it in 6 quarters since. The position peaked at $114K in Q2 2013. 116 funds tracked by Wall St. Rank hold SCLN as of Q3 2014.

  • UBS held 12,147 shares of Sciclone Pharmaceuticals Inc worth $83K as of Q3 2014.
  • UBS sold 2,367 Sciclone Pharmaceuticals Inc shares in Q3 2014, an estimated $14.2K.
  • Sciclone Pharmaceuticals Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6223 holding.
  • UBS first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Sciclone Pharmaceuticals Inc position peaked at $114K in Q2 2013.
  • 116 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.